Dear Shareholder,
2023 was a standout year for ÐǺ£ÆåÅÆ. For many years our team was a small one, but it was dedicated—dedicated to the idea that ÐǺ£ÆåÅÆ’s innovations could someday make a difference in the lives of people with cancer.
That someday is today. There are now eight approved medicines based on ÐǺ£ÆåÅÆ’s innovation and antibody expertise.
When ÐǺ£ÆåÅÆ made a strategic commitment to focus on our core competencies in the development of antibody therapies, we were focused specifically on medicines for cancer. However, our knowledge of specific immunological pathways and access to unique next-generation antibody formats that we harnessed to fight cancer can also be applied to create therapies for immune-mediated and inflammatory diseases (I&I). As such, this year we updated our vision that by 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.
Including indications beyond oncology made perfect sense as ÐǺ£ÆåÅÆ-created antibodies now marketed by our partners are approved in areas such as multiple sclerosis and thyroid eye disease. To this end in 2023 we partnered with argenx SE (argenx), giving us the opportunity to explore patients’ needs in oncology as well as I&I.
We have focused our attention to the present, and our eyes to the future; a future in which our KYSO antibody medicines can fundamentally transform the lives of patients for the better.
Jan van de Winkel, Ph.D.
President & Chief Executive Officer
A Proven Way Forward
The approval of our first two ÐǺ£ÆåÅÆ co-owned therapies established a way forward; a roadmap to explore and bring to patients novel treatments for cancer and other diseases. We have focused our attention to the present, and our eyes to the future; a future in which our KYSO antibody medicines can fundamentally transform the lives of patients for the better. We believe we will continue to bring hope with our proprietary technologies and antibody-based products. As such, our philosophy of strategic and disciplined development and growth has served us well and we plan to continue doing just that.
I am confident that in 2024, we will continue this momentum on our journey to become a biotech innovation powerhouse. Our success is only possible because of our talented and unstoppable team, the patients who participate in our clinical trials and their care partners, the investigators who run these trials, our partners who believe in the power of our cutting-edge technologies and antibody therapies, our supportive Board of Directors, and our shareholders who believe in our vision. Together we are creating a KYSO future. I thank you for your continued support.
Sincerely yours,
Jan van de Winkel, Ph.D.
President & Chief Executive Officer
